
Global Oral Antidiabetic Agents Market Growth (Status and Outlook) 2025-2031
Description
According to this study, the global Oral Antidiabetic Agents market size will reach US$ million by 2031.
Oral Antidiabetic Agents refer to the oral drugs used to treat type 2 diabetes in patients who uncontrolled by diet and exercise. Currently, there are five distinct classes of hypoglycemic agents available include sulfonylureas, meglitinides, biguanides, thiazolidinediones and alpha-glucosidase inhibitors.
United States market for Oral Antidiabetic Agents is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Oral Antidiabetic Agents is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Oral Antidiabetic Agents is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Oral Antidiabetic Agents players cover Novo Nordisk, Eli Lilly, Sanofi, Roche, Teva, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Oral Antidiabetic Agents Industry Forecast” looks at past sales and reviews total world Oral Antidiabetic Agents sales in 2024, providing a comprehensive analysis by region and market sector of projected Oral Antidiabetic Agents sales for 2025 through 2031. With Oral Antidiabetic Agents sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oral Antidiabetic Agents industry.
This Insight Report provides a comprehensive analysis of the global Oral Antidiabetic Agents landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Oral Antidiabetic Agents portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oral Antidiabetic Agents market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oral Antidiabetic Agents and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oral Antidiabetic Agents.
This report presents a comprehensive overview, market shares, and growth opportunities of Oral Antidiabetic Agents market by product type, application, key players and key regions and countries.
Segmentation by Type:
Sulfonylureas
Meglitinides
Biguanides
Thiazolidinediones
Alpha-glucosidase Inhibitors
Segmentation by Application:
Home Use
Medical Institutions
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novo Nordisk
Eli Lilly
Sanofi
Roche
Teva
AstraZeneca
Wockhardt UK
Merck
Pfizer
Cipla
Please note: The report will take approximately 2 business days to prepare and deliver.
Oral Antidiabetic Agents refer to the oral drugs used to treat type 2 diabetes in patients who uncontrolled by diet and exercise. Currently, there are five distinct classes of hypoglycemic agents available include sulfonylureas, meglitinides, biguanides, thiazolidinediones and alpha-glucosidase inhibitors.
United States market for Oral Antidiabetic Agents is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Oral Antidiabetic Agents is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Oral Antidiabetic Agents is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Oral Antidiabetic Agents players cover Novo Nordisk, Eli Lilly, Sanofi, Roche, Teva, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Oral Antidiabetic Agents Industry Forecast” looks at past sales and reviews total world Oral Antidiabetic Agents sales in 2024, providing a comprehensive analysis by region and market sector of projected Oral Antidiabetic Agents sales for 2025 through 2031. With Oral Antidiabetic Agents sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oral Antidiabetic Agents industry.
This Insight Report provides a comprehensive analysis of the global Oral Antidiabetic Agents landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Oral Antidiabetic Agents portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oral Antidiabetic Agents market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oral Antidiabetic Agents and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oral Antidiabetic Agents.
This report presents a comprehensive overview, market shares, and growth opportunities of Oral Antidiabetic Agents market by product type, application, key players and key regions and countries.
Segmentation by Type:
Sulfonylureas
Meglitinides
Biguanides
Thiazolidinediones
Alpha-glucosidase Inhibitors
Segmentation by Application:
Home Use
Medical Institutions
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novo Nordisk
Eli Lilly
Sanofi
Roche
Teva
AstraZeneca
Wockhardt UK
Merck
Pfizer
Cipla
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
81 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Oral Antidiabetic Agents Market Size by Player
- 4 Oral Antidiabetic Agents by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Oral Antidiabetic Agents Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.